The American Diabetes Association faces renewed scrutiny over its clinical guidelines, with critics warning that its emphasis on expensive drug therapies like Ozempic and Wegovy risks widening health disparities and sidelining preventive care strategies. The American Diabetes Association is under…

The rise of continuous glucose monitors among non-diabetics, driven by social media and biohacking, sparks both curiosity and caution among health experts over their accuracy, benefits, and potential psychological impact. Continuous glucose monitors, once a largely clinical tool for people…

Advances in continuous glucose monitoring technology are expanding beyond insulin users, offering new insights for type 2 diabetes management and health optimisation, but require effective patient education and awareness of potential drawbacks. Continuous glucose monitoring is increasingly being positioned as…

Patients often face sudden increases in insulin costs, not from coverage changes, but due to complex formulary revisions and rebate arrangements overseen by pharmacy benefit managers, highlighting opaque drug pricing practices. Many people are startled when the price of insulin…

A recent study reveals genetically engineered donor islet cells functioning 14 months post-transplant without immunosuppressants, marking a significant step towards a potential cure for type 1 diabetes amidst ongoing technological and ethical debates. Recent developments in diabetes care are pointing…

Recent advances in drug development are shifting the landscape of type 1 diabetes from symptomatic management to disease modification and potential insulin independence, driven by novel therapies like Sanofi’s Tzield and emerging cell-based approaches. Type 1 diabetes research is moving…

Recent meta-analyses reveal GLP-1 drugs as highly effective for weight loss, but outcomes depend on individual responses, treatment maintenance, and ongoing management strategies. GLP-1 medicines have moved weight-loss treatment into a new phase. According to a 2024 meta-analysis published in…

Researchers at the Technical University of Denmark have developed a free online self-assessment tool, MEDWACS, which can identify individuals at risk of prediabetes or type 2 diabetes using simple measurements, potentially years before symptoms appear. A new artificial intelligence tool…

The global market for dipeptidyl peptidase-4 inhibitors is projected to expand to $14.78 billion by 2030, propelled by rising diabetes prevalence, increasing access to care, and the shift towards affordable oral therapies and generics, with major companies competing on scale…